611 W. Union Street
Benson, AZ 85602
(520) 586-0800

member support line
M-F 5pm-8pm
24/7 weekends/holidays

AzCH Nurse Assist Line


611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line


powered by centersite dot net
Medical Disorders
Basic InformationLookupsLatest News
Teens' Heart Risk From COVID Far Exceeds That of Vaccination: StudyCould COVID-19 Accelerate Alzheimer's Symptoms?New Data Details Dangers of Delta Variant, Even for the VaccinatedCDC Now Says Vaccinated Should Be Tested After COVID Exposure, Even Without SymptomsWhy Strokes Can Affect Women, Men DifferentlyMore Than Half of Americans Plagued by Back, Leg PainPfizer Says 3rd Shot of Vaccine Boosts COVID ProtectionVitamin D May Lower Black Women's Odds for COVID-19Primary Care Doctors Often Miss Heart Failure in Women, Black PatientsBogus Info on Cancer Common Online, and It Can HarmDelta Variant Spreads More Easily, Causing CDC Change on Indoor MaskingSevere COVID for People Under 45: Who's Most at Risk?The Heat Is On: Staying Safe When Temperatures SoarWho's Most Likely to Refuse a COVID Vaccine?Second COVID Shot Safe in Folks Who Had Allergic Reaction to FirstHigh Blood Pressure: Which Drug Works Best for You?Pfizer, Moderna to Expand Vaccine Studies in Young ChildrenFederal, State Moves Begin to Mandate COVID Vaccines for WorkersCan COVID Transmit Easily on Crowded School Buses?Worried About Delta-Linked 'Breakthrough' Infections? Experts Explain the RisksMajor Medical Groups Call for Mandatory COVID Vaccination for Health WorkersU.S. to Stick With International Travel RestrictionsSurvey Finds U.S. Parents Split on COVID Vaccination for Kids Under 12Most Unvaccinated Americans Want to Stay That Way: PollIt's Tick Season: Protect Yourself From Lyme DiseaseHigh-Tech Exoskeletons Improve Bowel Function in People With Spinal Cord Injury'Superbug' Fungus Spreads Among Vulnerable in Two U.S. CitiesVaccinations Start to Climb in States Hit Hard by Delta VariantAs Olympics Begin, Tokyo Posts Highest Number of New COVID Cases in Six MonthsVirtual Roller Coaster Ride Study Brings New Insights Into MigraineBiden Says Full Approval for COVID Vaccines Coming SoonPfizer Vaccine Offers 88% Protection Against Delta Variant, But 2 Doses NeededSecret Weapon: Why the 2nd Dose of Pfizer Vaccine Is So CrucialIn a First for the Continent, Pfizer COVID-19 Vaccine Will Be Produced in South AfricaLockdowns' Effects on Health Still Less Than Harm From Pandemic: ExpertsCOVID Drove Biggest Drop in U.S. Life Expectancy Since World War IIJ&J Vaccine Weak Against Delta Variant, 2nd Dose May Be NeededDouble Trouble: Wildfire Smoke Could Boost Odds for COVID's SpreadStatin Users May Have Added Protection Against Severe COVID-19Severe COVID in Kids: Rare, but Brain Issues Can ResultOne-Dose Blood Thinner Could Slash Blood Clot Risk After Knee ReplacementU.S. Issues Toughest Travel Alert for Britain As COVID Cases There ClimbPediatricians' Group: All School Kids, Staff Should Continue to Wear MasksGeneticists Probe Origins of Painful Cluster HeadachesAny COVID Infection Leaves Strong Antibody Levels in KidsMany Hit Hard by Pandemic Now Swamped by Medical DebtU.S. Surgeon General Backs Local Mask Mandates When NeededMake Summer Camp Safe for Your Child With Asthma, AllergiesCanada May Open Borders to Fully Vaccinated Americans by Mid-AugustCDC Advisors to Discuss 3rd COVID Vaccine Dose for Immunocompromised
Questions and AnswersLinksBook Reviews
Related Topics

Men's Health
Women's Health

One-Dose Blood Thinner Could Slash Blood Clot Risk After Knee Replacement

HealthDay News
by By Ernie Mundell and Robert Preidt HealthDay Reporters
Updated: Jul 20th 2021

new article illustration

TUESDAY, July 20, 2021 (HealthDay News) -- Anyone who's ever undergone knee replacement understands the real and troubling risk of post-op blood clots. Many patients are told take a daily blood thinner pill long after their procedure.

But a new study finds that a one-time injection of an experimental blood thinner called abelacimab may greatly reduce the odds for these clots in recovering knee replacement patients.

The researchers compared abelacimab with another prescription blood thinner called enoxaparin (brand name Lovenox) in 412 patients undergoing knee replacement.

Compared to enoxaparin, a single injection of abelacimab reduced the risk of blood clots by 80% for up to a month after surgery, and didn't increase the risk of bleeding — a common side effect with blood thinners.

"Patients who undergo knee replacement routinely receive anti-clotting treatment with enoxaparin or other anticoagulant medications that require daily administration," said research team leader Jeffrey Weitz. He's a hematologist and professor of medicine and of biochemistry and biomedical sciences at McMaster University in Hamilton, Canada. He's also executive director of the university's Thrombosis and Atherosclerosis Research Institute.

"With a single injection of abelacimab after surgery, we found much better protection against clots in the veins in the leg [deep vein thrombosis, or DVTs] compared with enoxaparin, one of the current standards of care," Weitz said in a McMaster news release.

The study was funded by Massachusetts-based Anthos Therapeutics, which is developing abelacimab. The report was published July 19 in the New England Journal of Medicine and also presented at a meeting of the International Society on Thrombosis and Haemostasis.

According to the research team, abelacimab is an antibody that binds to both the inactive and activated forms of a clotting factor called factor XI, preventing its activation and activity, and halting clot formation.

One expert unconnected to the study said the drug shows some promise.

"DVT formation is a significant fear in lower-extremity orthopedic surgery. This drug could be applied not only to total joint replacement, but also to fracture treatment. I'll look forward to further research," said Dr. Jeffrey Schildhorn, an orthopedic surgeon at Lenox Hill Hospital in New York City.

The treatment's convenience is also a huge plus, Schildhorn said. Patients only need the one-time injection and compliance should rise because they don't need to remember to take a daily blood thinner pill, he added.

Still, there are unanswered questions, Schildhorn said. What if rare cases of excessive bleeding arise when abelacimab is used?

"If excess bleeding occurs in some patients, are the effects of this medication reversible? What agents are used to reverse the anticoagulant effects [that might lead to bleeding], and how much time is required for the effects to wane?" he wondered. Only further research can help answer those questions, Schildhorn said.

For their part, the research team believes that the positive findings from their trial suggest that abelacimab may help treat other cardiovascular conditions.

For example, Weitz said, the drug might be used "for prevention of stroke in patients with atrial fibrillation and for treatment of deep-vein thrombosis and pulmonary embolism — clots in the veins of the leg and clots in the lung," and in cancer patients.

More information

The American Society of Hematology has more on blood clots.

SOURCES: Jeffrey Schildhorn MD, orthopedic surgeon, Lenox Hill Hospital, New York City; McMaster University, news release, July 19, 2021